EA201992771A1 - Ингибитор поверхностного антигена вируса гепатита b - Google Patents

Ингибитор поверхностного антигена вируса гепатита b

Info

Publication number
EA201992771A1
EA201992771A1 EA201992771A EA201992771A EA201992771A1 EA 201992771 A1 EA201992771 A1 EA 201992771A1 EA 201992771 A EA201992771 A EA 201992771A EA 201992771 A EA201992771 A EA 201992771A EA 201992771 A1 EA201992771 A1 EA 201992771A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
surface antigen
virus surface
antigen inhibitor
formula
Prior art date
Application number
EA201992771A
Other languages
English (en)
Other versions
EA039824B1 (ru
Inventor
Чарлз З. Дин
Фэй Сунь
Яньбинь Ху
Шухуэй Чэнь
Original Assignee
Фуцзянь Косантер Фармасьютикал Ко., Лтд.
Медшайн Дискавери Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фуцзянь Косантер Фармасьютикал Ко., Лтд., Медшайн Дискавери Инк. filed Critical Фуцзянь Косантер Фармасьютикал Ко., Лтд.
Publication of EA201992771A1 publication Critical patent/EA201992771A1/ru
Publication of EA039824B1 publication Critical patent/EA039824B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

В настоящем изобретении раскрыто новое производное 11-оксо-7,11-дигидро-6h-бензо[f]пиридо[1,2-d][1,4]азепиноксепин-10-карбоновой кислоты, которое осуществляет функции ингибитора поверхностного антигена вируса гепатита B. Конкретно, раскрыто соединение, представленное формулой (V), или его фармацевтически приемлемая соль и применение соединения, представленного формулой (V), или его фармацевтически приемлемой соли и его фармацевтической композиции для лечения вирусного гепатита B.
EA201992771A 2017-05-22 2018-05-22 Ингибитор поверхностного антигена вируса гепатита b EA039824B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710365328 2017-05-22
PCT/CN2018/087852 WO2018214875A1 (zh) 2017-05-22 2018-05-22 乙型肝炎病毒表面抗原抑制剂

Publications (2)

Publication Number Publication Date
EA201992771A1 true EA201992771A1 (ru) 2020-03-23
EA039824B1 EA039824B1 (ru) 2022-03-17

Family

ID=64396235

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992771A EA039824B1 (ru) 2017-05-22 2018-05-22 Ингибитор поверхностного антигена вируса гепатита b

Country Status (11)

Country Link
US (1) US20200197409A1 (ru)
EP (1) EP3632914B1 (ru)
JP (1) JP7072003B2 (ru)
KR (1) KR102546873B1 (ru)
CN (1) CN110372723B (ru)
AU (1) AU2018271643B2 (ru)
BR (1) BR112019024393A2 (ru)
CA (1) CA3062499C (ru)
EA (1) EA039824B1 (ru)
MX (1) MX2019013815A (ru)
WO (1) WO2018214875A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110066278B (zh) 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
WO2020051375A2 (en) 2018-09-05 2020-03-12 Children's Medical Center Corporation Papd5 inhibitors and methods of use thereof
EP3856740A4 (en) 2018-09-30 2021-12-15 Sunshine Lake Pharma Co., Ltd. CONDENSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
AU2019382521B2 (en) * 2018-11-22 2023-11-16 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of hepatitis B surface antigen inhibitor
US20220306648A1 (en) * 2019-08-15 2022-09-29 Fujian Akeylink Biotechnology Co., Ltd. Preparation Method for Oxazepine Compound
EP4151221A4 (en) * 2020-05-15 2023-11-15 Fujian Akeylink Biotechnology Co., Ltd. COMBINATION COMPRISING A TRICYCLIC COMPOUND AND ITS USE IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF HBV

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065687A1 (en) * 2007-04-17 2011-03-17 Michael Schwaebe Hydrazide compounds and uses thereof
EA201691261A1 (ru) * 2014-01-30 2016-11-30 Ф. Хоффманн-Ля Рош Аг Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
WO2017013046A1 (en) * 2015-07-21 2017-01-26 F. Hoffmann-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
CA3031063A1 (en) 2016-07-29 2018-02-01 Newave Pharmaceutical Inc. Benzo-quinolizin-2oxo carboxylic acid derivatives for the treatment of hbv infection
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same

Also Published As

Publication number Publication date
CN110372723A (zh) 2019-10-25
EP3632914B1 (en) 2022-08-31
JP7072003B2 (ja) 2022-05-19
EA039824B1 (ru) 2022-03-17
EP3632914A4 (en) 2020-04-22
CA3062499C (en) 2024-05-07
EP3632914A1 (en) 2020-04-08
JP2020520958A (ja) 2020-07-16
KR20200027925A (ko) 2020-03-13
AU2018271643A1 (en) 2020-01-02
BR112019024393A2 (pt) 2020-06-09
US20200197409A1 (en) 2020-06-25
CA3062499A1 (en) 2018-11-29
MX2019013815A (es) 2020-07-28
AU2018271643B2 (en) 2022-06-02
WO2018214875A1 (zh) 2018-11-29
KR102546873B1 (ko) 2023-06-26
CN110372723B (zh) 2022-05-31

Similar Documents

Publication Publication Date Title
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
EA201992082A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
NZ729150A (en) Antiretroviral agents
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
MY200608A (en) Hiv inhibitor compounds
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
PH12015501881A1 (en) Amide compounds for the treatment of hiv
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
SG11201901894TA (en) Anti-influenza virus pyrimidine derivatives
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EA202190602A2 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса
EA201590006A1 (ru) Комбинация терапевтических средств для лечения инфекции, вызванной вирусом гепатита c
CY1118920T1 (el) Ενωσεις πιπεραζινης- πιπεριδινης ως αναστολεις του ιου ηπατιτιδας c
EA202192760A1 (ru) Трициклические соединения
EA202190458A1 (ru) Составы, содержащие дендример
EA202192343A1 (ru) Пангенотипичный ингибитор белка ns5a вируса гепатита с, фармацевтическая композиция и способы их получения и применения
EA202190689A1 (ru) Производные хинолина в качестве ингибиторов интегрина альфа4бета7
EA201991910A1 (ru) Трициклическое соединение и пути его применения